Pituitary Gland News and Research

RSS

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round.

27 Feb 2015

Harmless plant extract can help treat Cushing Disease

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness.

16 Feb 2015

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life.

16 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.

16 Jan 2015

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

The FK506-binding protein 51 (FKBP51) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the very similar functional counterplayer FKBP52.

3 Dec 2014

PET/CT may improve differentiation of PTSD from MTBI

Hybrid imaging with positron emission tomography and computed tomography (PET/CT) in the pituitary region of the brain is a promising tool for differentiating military veterans with post-traumatic stress disorder (PTSD) from those with mild traumatic brain injury (MTBI), according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2014

Researchers discover molecular switch that triggers stress processes in the brain

At the Center for Brain Research at the MedUni Vienna an important factor for stress has been identified in collaboration with the Karolinska Institutet in Stockholm (Sweden). This is the protein secretagogin that plays an important role in the release of the stress hormone CRH and which only then enables stress processes in the brain to be transmitted to the pituitary gland and then onwards to the organs.

28 Nov 2014

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of acromegaly, a rare condition caused by excess growth hormone in the blood.

31 Oct 2014

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Ectopic tumours secreting corticotropin-releasing hormone and adrenocorticotropic hormone are very rare in children and can result in a misdiagnosis of Cushing’s disease, say researchers.

30 Oct 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Fitnessedge.net adds new articles on using hGH peptides for anti-aging, hGH replacement therapy

Fitnessedge.net, a website that is devoted to offering readers the most up-to-date information about various weight loss programs, has just added some new and educational articles on using hGH peptides for anti-aging and hGH replacement therapy.

26 Jul 2014

Growth hormone deficiency may protect people from developing Type 2 diabetes, cancer

People who lack growth hormone (GH) receptors also appear to have marked insulin sensitivity that prevents them from developing diabetes and lowers their risk for cancer, despite their increased percentage of body fat, new research finds.

24 Jun 2014

Study presents oxytocin as latest treatment target for age-related muscle wasting

Researchers at the University of California, Berkeley, have discovered that oxytocin -- a hormone associated with maternal nurturing, social attachments, childbirth and sex -- is indispensable for healthy muscle maintenance and repair, and that in mice, it declines with age.

11 Jun 2014

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula.

19 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.

24 Jan 2014

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

A team led by investigators from Massachusetts General Hospital, Brigham and Women's Hospital and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.

13 Jan 2014